Impacto de las alertas farmacoterapéuticas sobre la prescripción de clopidogrel e inhibidores de la bomba de protones en pacientes ingresados

Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que...

Full description

Saved in:
Bibliographic Details
Published inFarmacia hospitalaria Vol. 36; no. 4; pp. 250 - 255
Main Authors Sánchez Ruiz-Gordoa, M., Tenías Burillo, J.M., Ruiz Martín de la Torre, R., Valenzuela Gámez, J.C.
Format Journal Article
LanguageSpanish
Published Elsevier Espana 01.07.2012
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que se relacionaron con la prescripción conjunta. Estudio observacional, analítico, longitudinal y retrospectivo en el que se evaluaron los cambios de prescripción de la asociación clopidogrel-IBP antes y después de la primera alerta oficial publicada. Se seleccionaron los pacientes que presentaron en el conjunto mínimo básico de datos (CMBD) algún código que incluyera enfermedad del sistema circulatorio, a los que se les prescribió durante su ingreso clopidogrel. Se registró el consumo concomitante de IBP (omeprazol y pantoprazol) en estos pacientes. Ingresaron 5.678 pacientes con diagnóstico de enfermedad circulatoria, de los que 13,6% llevaron clopidogrel durante el ingreso. En la fase prealerta la prescripción combinada fue significativamente mayor (80,8 vs 48,6). La prescripción conjunta disminuyó si el diagnóstico circulatorio fue el motivo principal de ingreso, si la enfermedad fue cardiaca, si el servicio médico de ingreso fue medicina interna/cardiología o medicina intensiva y cuantas más semanas transcurrieron tras la alerta. Ha disminuido la prescripción conjunta desde la primera alerta; sobre todo si el motivo de ingreso principal era circulatorio cardiaco y en el caso de omeprazol, que inhibe en mayor grado que pantoprazol el CYP2C19. Los servicios médicos más relacionados con las enfermedades circulatorias se adhieren más a las directrices de las alertas. to estimate the frequency of clopidogrel prescriptions in association with proton pump inhibitors (PPIs) in patients hospitalised with circulatory pathologies, after the publication of several warnings about this association. To identify and quantify the magnitude of the factors related to the prescription of both drugs. observational, analytical, longitudinal, and retrospective study assessing changes in prescription of clopidogrel-PPIs association after and before the first official warning (about these drugs’ interactions) was published. We selected all patients with a code indicating a circulatory system disease in the Minimum Basic Data Set, who had been prescribed clopidogrel during hospital admission. We also evaluated proton pump inhibitor use in these patients (omeprazole and pantoprazole). 5678 patients diagnosed with circulatory diseases were admitted during 2009, and clopidogrel was prescribed in 13.6% of them. In the pre-warning period, clopidogrel-PPIs prescriptions were significantly higher than in the post-warning period (80, 8% vs 48, 6%), especially in omeprazole. The combined prescription was lower if the circulatory diagnosis was the main cause for hospitalisation, if the patient had heart disease, if the patient was admitted in Internal Medicine/Cardiology or Intensive care units, and if the period of time was further from warning. combined prescription has decreased since the first warning, above all in patients with a primary circulatory heart disease. Omeprazole is a potent CYP2C19 inhibitor, so it was used in lower rates than pantoprazole in association with clopidogrel. Medical departments related to cardiovascular disease followed the warning more than others.
AbstractList Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que se relacionaron con la prescripción conjunta. Estudio observacional, analítico, longitudinal y retrospectivo en el que se evaluaron los cambios de prescripción de la asociación clopidogrel-IBP antes y después de la primera alerta oficial publicada. Se seleccionaron los pacientes que presentaron en el conjunto mínimo básico de datos (CMBD) algún código que incluyera enfermedad del sistema circulatorio, a los que se les prescribió durante su ingreso clopidogrel. Se registró el consumo concomitante de IBP (omeprazol y pantoprazol) en estos pacientes. Ingresaron 5.678 pacientes con diagnóstico de enfermedad circulatoria, de los que 13,6% llevaron clopidogrel durante el ingreso. En la fase prealerta la prescripción combinada fue significativamente mayor (80,8 vs 48,6). La prescripción conjunta disminuyó si el diagnóstico circulatorio fue el motivo principal de ingreso, si la enfermedad fue cardiaca, si el servicio médico de ingreso fue medicina interna/cardiología o medicina intensiva y cuantas más semanas transcurrieron tras la alerta. Ha disminuido la prescripción conjunta desde la primera alerta; sobre todo si el motivo de ingreso principal era circulatorio cardiaco y en el caso de omeprazol, que inhibe en mayor grado que pantoprazol el CYP2C19. Los servicios médicos más relacionados con las enfermedades circulatorias se adhieren más a las directrices de las alertas. to estimate the frequency of clopidogrel prescriptions in association with proton pump inhibitors (PPIs) in patients hospitalised with circulatory pathologies, after the publication of several warnings about this association. To identify and quantify the magnitude of the factors related to the prescription of both drugs. observational, analytical, longitudinal, and retrospective study assessing changes in prescription of clopidogrel-PPIs association after and before the first official warning (about these drugs’ interactions) was published. We selected all patients with a code indicating a circulatory system disease in the Minimum Basic Data Set, who had been prescribed clopidogrel during hospital admission. We also evaluated proton pump inhibitor use in these patients (omeprazole and pantoprazole). 5678 patients diagnosed with circulatory diseases were admitted during 2009, and clopidogrel was prescribed in 13.6% of them. In the pre-warning period, clopidogrel-PPIs prescriptions were significantly higher than in the post-warning period (80, 8% vs 48, 6%), especially in omeprazole. The combined prescription was lower if the circulatory diagnosis was the main cause for hospitalisation, if the patient had heart disease, if the patient was admitted in Internal Medicine/Cardiology or Intensive care units, and if the period of time was further from warning. combined prescription has decreased since the first warning, above all in patients with a primary circulatory heart disease. Omeprazole is a potent CYP2C19 inhibitor, so it was used in lower rates than pantoprazole in association with clopidogrel. Medical departments related to cardiovascular disease followed the warning more than others.
Author Valenzuela Gámez, J.C.
Sánchez Ruiz-Gordoa, M.
Tenías Burillo, J.M.
Ruiz Martín de la Torre, R.
Author_xml – sequence: 1
  givenname: M.
  surname: Sánchez Ruiz-Gordoa
  fullname: Sánchez Ruiz-Gordoa, M.
  email: msanchezruizdegordoa@yahoo.es
  organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España
– sequence: 2
  givenname: J.M.
  surname: Tenías Burillo
  fullname: Tenías Burillo, J.M.
  organization: Unidad de Apoyo a la Investigación, Área IDF, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España
– sequence: 3
  givenname: R.
  surname: Ruiz Martín de la Torre
  fullname: Ruiz Martín de la Torre, R.
  organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España
– sequence: 4
  givenname: J.C.
  surname: Valenzuela Gámez
  fullname: Valenzuela Gámez, J.C.
  organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España
BookMark eNp9kEtOwzAQhr0oEm3hBGx8gYRxHk6yYIEqHpUqsYG15ccEXCVxZAckTsE5WHOEXgynZc1qHprvn5l_RRaDG5CQKwYpA8av92krfS_TDBhLoU4BsgVZMpZDwvMiPyerEPYAZVZlbEm-tv0o9eSoQdrJQGWHforxqKHdhF6Oh-_3yerYDE75eYyOHoP2dtT28DPMqO7caI179dhRpHZ4syqWceqkS5XrlZzz0bsp3hsoDjQutjhMsbBDJIM0LlyQs1Z2AS__4pq83N89bx6T3dPDdnO7SzTjTZZwaOoaGwYFKix0bZqcK57VrFS8rnLJmkoWpgDdVExxgw2vWAOtLsvSaFAsX5P8pKu9C8FjK0Zve-k_BQMx-yj24uiBmH0UUIvoY6RuThTG0z4sehHmFzQa61FPwjj7L_8LoW-Eow
Cites_doi 10.1111/j.1538-7836.2006.02162.x
10.1177/0091270008315310
10.1016/j.amjcard.2009.10.063
10.1016/S0140-6736(09)61562-2
10.7326/0003-4819-153-6-201009210-00011
10.1001/archinte.166.3.338
10.1016/j.jacc.2008.08.002
10.1161/circ.118.suppl_18.S_815-a
10.1016/j.jacc.2007.06.064
10.1001/jama.287.19.2504-a
10.1161/circ.118.suppl_18.S_815
ContentType Journal Article
Copyright 2011 SEFH
Copyright_xml – notice: 2011 SEFH
DBID AAYXX
CITATION
DOI 10.1016/j.farma.2011.08.002
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Impact of pharmacotherapeutic warnings on the prescription of clopidogrel and proton pump inhibitors in hospitalised patients
EndPage 255
ExternalDocumentID 10_1016_j_farma_2011_08_002
S1130634311001991
GroupedDBID --K
0R~
2WC
4.4
53G
5GY
5VS
AAEDT
AALRI
AAWTL
AAXUO
ABXHO
ACGFS
ADBBV
ADCUG
AEKER
AITUG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APOWU
AZFZN
BAWUL
BCNDV
DIK
E3Z
EBS
EJD
FDB
FNPLU
GROUPED_DOAJ
GX1
HZ~
IPNFZ
M41
O-L
O9-
OK1
P-8
P-9
RIG
ROL
RSK
SCD
SDF
SES
Z7D
0SF
AAYXX
ADVLN
AKRWK
CITATION
ID FETCH-LOGICAL-c1692-60988e9104ebe4c8d936b62815b6873a197a4d40c971b6de967190fc555dc0b13
ISSN 1130-6343
IngestDate Fri Aug 23 03:54:30 EDT 2024
Fri Feb 23 02:24:57 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Warning
Interacción
Clopidogrel
Alerta
Proton pump inhibitors
Inhibidores de la bomba de protones
Drug-drug interaction
Language Spanish
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1692-60988e9104ebe4c8d936b62815b6873a197a4d40c971b6de967190fc555dc0b13
OpenAccessLink https://doi.org/10.1016/j.farma.2011.08.002
PageCount 6
ParticipantIDs crossref_primary_10_1016_j_farma_2011_08_002
elsevier_sciencedirect_doi_10_1016_j_farma_2011_08_002
PublicationCentury 2000
PublicationDate July-August 2012
PublicationDateYYYYMMDD 2012-07-01
PublicationDate_xml – month: 07
  year: 2012
  text: July-August 2012
PublicationDecade 2010
PublicationTitle Farmacia hospitalaria
PublicationYear 2012
Publisher Elsevier Espana
Publisher_xml – name: Elsevier Espana
References Bhatt, Scheiman, Abraham, Antman, Chan, Furberg (bib0005) 2008; 52
Servicio de Farmacia La Mancha Centro. Página web. Disponible en
Gaglia, Torguson, Hanna, Gonzalez, Collins, Syed Al (bib0050) 2010; 105
and Prilosec OTC) [17 Nov 2009].
Aubert, Epstein, Teagarden, Xia, Yao, Desta (bib0035) 2008; 118
Horlen, Malone, Bryant, Dennis, Carey, Pignone (bib0100) 2002; 287
Gilard, Arnaud, Le, Abgrall, Boschat (bib0020) 2006; 4
Bhatt DL, Gyer B, Charles F, Cohen M, Lanas A, Schnitzer TJ, et al. COGENT: a prospective, randomized, placebo-controlled trial. TCT 2009 Meeting San Francisco, California. 24/09/2009. Disponible en
Aquino, Brophy (bib0085) 2010; 153
Lasser, Seger, Yu, Karson, Fiskio, Seger (bib0095) 2006; 166
Gilard, Arnaud, Cornily, Le, Lacut, Le (bib0025) 2008; 51
Agencia Española de Medicamentos y Productos Sanitarios AEMPS. Posible interacción de clopidogrel con los inhibidores de la bomba de protones [3 Jun 2009]. Disponible en
Sibbing, Kastrati (bib0055) 2009; 374
Food and Drugs Administration. Information for healthcare profesionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix
Inhibidores de la bomba de protones: ¿se puede vivir sin ellos? Boletín INFAC. 2010;18:3. Disponible en
Dunn, Macaulay, Brennan, Campbell, Charnigo, Smyth (bib0040) 2008; 118
Small, Farid, Pauyne, Weerakkody, Li, Brandt (bib0030) 2008; 48
Ricci, Coulen, Berger, Moore, McQueen Ajan (bib0090) 2009; 15
Latour (bib0010) 2009; 9
European Medicines Agency. Interaction between clopidogrel and proton pump ihibitors [17 Mar 2010]. Disponible en
AEMPS. Interacción de clopidogrel con los inhibidores de la bomba de protones: actualización de la información y recomendaciones de uso [27 Abril 2010]. Disponible en
to alert heathcare professionals about a drug interaction with omeprazole (marketed as Prilosec
Dunn (10.1016/j.farma.2011.08.002_bib0040) 2008; 118
Gilard (10.1016/j.farma.2011.08.002_bib0020) 2006; 4
Horlen (10.1016/j.farma.2011.08.002_bib0100) 2002; 287
10.1016/j.farma.2011.08.002_bib0080
Gaglia (10.1016/j.farma.2011.08.002_bib0050) 2010; 105
Latour (10.1016/j.farma.2011.08.002_bib0010) 2009; 9
10.1016/j.farma.2011.08.002_bib0060
10.1016/j.farma.2011.08.002_bib0070
Lasser (10.1016/j.farma.2011.08.002_bib0095) 2006; 166
Aquino (10.1016/j.farma.2011.08.002_bib0085) 2010; 153
10.1016/j.farma.2011.08.002_bib0015
Aubert (10.1016/j.farma.2011.08.002_bib0035) 2008; 118
Sibbing (10.1016/j.farma.2011.08.002_bib0055) 2009; 374
Bhatt (10.1016/j.farma.2011.08.002_bib0005) 2008; 52
10.1016/j.farma.2011.08.002_bib0075
Gilard (10.1016/j.farma.2011.08.002_bib0025) 2008; 51
10.1016/j.farma.2011.08.002_bib0065
Small (10.1016/j.farma.2011.08.002_bib0030) 2008; 48
10.1016/j.farma.2011.08.002_bib0045
Ricci (10.1016/j.farma.2011.08.002_bib0090) 2009; 15
References_xml – volume: 9
  start-page: A98
  year: 2009
  ident: bib0010
  article-title: ¿Debemos abandoner el uso conjunto de clopidogrel e inhibidores de la bomba de protones?
  publication-title: REMI
  contributor:
    fullname: Latour
– volume: 287
  start-page: 2504
  year: 2002
  end-page: 2505
  ident: bib0100
  article-title: Research letter: frequency of inappropriate metformin prescriptions
  publication-title: JAMA
  contributor:
    fullname: Pignone
– volume: 4
  start-page: 2508
  year: 2006
  end-page: 2509
  ident: bib0020
  article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin
  publication-title: J Thromb Haemost
  contributor:
    fullname: Boschat
– volume: 118
  start-page: S815
  year: 2008
  ident: bib0040
  article-title: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREEDO trial (Abstract)
  publication-title: Circulation
  contributor:
    fullname: Smyth
– volume: 153
  start-page: 413
  year: 2010
  end-page: 415
  ident: bib0085
  article-title: Conflicting evidence- what is a clinician to do?
  publication-title: Ann Intern Med
  contributor:
    fullname: Brophy
– volume: 374
  start-page: 952
  year: 2009
  end-page: 953
  ident: bib0055
  article-title: Risk of combining PPIs with thienopyridines: fact or fiction?
  publication-title: Lancet
  contributor:
    fullname: Kastrati
– volume: 51
  start-page: 256
  year: 2008
  end-page: 260
  ident: bib0025
  article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Le
– volume: 52
  start-page: 1502
  year: 2008
  end-page: 1517
  ident: bib0005
  article-title: ACCF/ACG/AHA Expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Furberg
– volume: 105
  start-page: 833
  year: 2010
  end-page: 838
  ident: bib0050
  article-title: Relation of Proton Pump Inhibitors use after percutaneous coronary intervention with drug-eluting stents to outcomes
  publication-title: Am J Cardiol
  contributor:
    fullname: Syed Al
– volume: 48
  start-page: 475
  year: 2008
  end-page: 484
  ident: bib0030
  article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
  publication-title: J Clin Pharmacol
  contributor:
    fullname: Brandt
– volume: 166
  start-page: 338
  year: 2006
  end-page: 344
  ident: bib0095
  article-title: Adherence to black box warnings for prescription medications in outpatients
  publication-title: Arch Intern Med
  contributor:
    fullname: Seger
– volume: 15
  start-page: 103
  year: 2009
  end-page: 108
  ident: bib0090
  article-title: Prescriber compliance with black box warnings in older adults patients
  publication-title: Am J Manag Care
  contributor:
    fullname: McQueen Ajan
– volume: 118
  start-page: S815
  year: 2008
  ident: bib0035
  article-title: Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study (Abstract)
  publication-title: Circulation
  contributor:
    fullname: Desta
– volume: 4
  start-page: 2508
  year: 2006
  ident: 10.1016/j.farma.2011.08.002_bib0020
  article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.02162.x
  contributor:
    fullname: Gilard
– volume: 48
  start-page: 475
  year: 2008
  ident: 10.1016/j.farma.2011.08.002_bib0030
  article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270008315310
  contributor:
    fullname: Small
– volume: 105
  start-page: 833
  year: 2010
  ident: 10.1016/j.farma.2011.08.002_bib0050
  article-title: Relation of Proton Pump Inhibitors use after percutaneous coronary intervention with drug-eluting stents to outcomes
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2009.10.063
  contributor:
    fullname: Gaglia
– volume: 374
  start-page: 952
  year: 2009
  ident: 10.1016/j.farma.2011.08.002_bib0055
  article-title: Risk of combining PPIs with thienopyridines: fact or fiction?
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61562-2
  contributor:
    fullname: Sibbing
– volume: 153
  start-page: 413
  year: 2010
  ident: 10.1016/j.farma.2011.08.002_bib0085
  article-title: Conflicting evidence- what is a clinician to do?
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-153-6-201009210-00011
  contributor:
    fullname: Aquino
– volume: 166
  start-page: 338
  year: 2006
  ident: 10.1016/j.farma.2011.08.002_bib0095
  article-title: Adherence to black box warnings for prescription medications in outpatients
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.166.3.338
  contributor:
    fullname: Lasser
– ident: 10.1016/j.farma.2011.08.002_bib0065
– volume: 52
  start-page: 1502
  year: 2008
  ident: 10.1016/j.farma.2011.08.002_bib0005
  article-title: ACCF/ACG/AHA Expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.08.002
  contributor:
    fullname: Bhatt
– ident: 10.1016/j.farma.2011.08.002_bib0060
– ident: 10.1016/j.farma.2011.08.002_bib0045
– ident: 10.1016/j.farma.2011.08.002_bib0080
– volume: 118
  start-page: S815
  year: 2008
  ident: 10.1016/j.farma.2011.08.002_bib0040
  article-title: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREEDO trial (Abstract)
  publication-title: Circulation
  doi: 10.1161/circ.118.suppl_18.S_815-a
  contributor:
    fullname: Dunn
– volume: 9
  start-page: A98
  year: 2009
  ident: 10.1016/j.farma.2011.08.002_bib0010
  article-title: ¿Debemos abandoner el uso conjunto de clopidogrel e inhibidores de la bomba de protones?
  publication-title: REMI
  contributor:
    fullname: Latour
– volume: 51
  start-page: 256
  year: 2008
  ident: 10.1016/j.farma.2011.08.002_bib0025
  article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2007.06.064
  contributor:
    fullname: Gilard
– ident: 10.1016/j.farma.2011.08.002_bib0015
– volume: 15
  start-page: 103
  year: 2009
  ident: 10.1016/j.farma.2011.08.002_bib0090
  article-title: Prescriber compliance with black box warnings in older adults patients
  publication-title: Am J Manag Care
  contributor:
    fullname: Ricci
– volume: 287
  start-page: 2504
  year: 2002
  ident: 10.1016/j.farma.2011.08.002_bib0100
  article-title: Research letter: frequency of inappropriate metformin prescriptions
  publication-title: JAMA
  doi: 10.1001/jama.287.19.2504-a
  contributor:
    fullname: Horlen
– volume: 118
  start-page: S815
  year: 2008
  ident: 10.1016/j.farma.2011.08.002_bib0035
  article-title: Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study (Abstract)
  publication-title: Circulation
  doi: 10.1161/circ.118.suppl_18.S_815
  contributor:
    fullname: Aubert
– ident: 10.1016/j.farma.2011.08.002_bib0070
– ident: 10.1016/j.farma.2011.08.002_bib0075
SSID ssj0052721
Score 1.8142573
Snippet Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 250
SubjectTerms Alerta
Clopidogrel
Drug-drug interaction
Inhibidores de la bomba de protones
Interacción
Proton pump inhibitors
Warning
Title Impacto de las alertas farmacoterapéuticas sobre la prescripción de clopidogrel e inhibidores de la bomba de protones en pacientes ingresados
URI https://dx.doi.org/10.1016/j.farma.2011.08.002
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbpwwELZW6aWXqr9q-icfqlxYEBgw-NikzaaRUkXVptobwtgoGzUQhd1D9iX6HD33EfJAfYXO2PypiaKmF4RgMIb5sGeGmc-EvGc54zljiZvLqHSjSElXpn7pxiCvC-VzVWJo4OgLPziJDhfxYjL5PcpaWq-kV2xurSv5H63CMdArVsneQ7N9o3AA9kG_sAUNw_afdPzZlDjWjtIOGMEOjPVgSzdOadmosbb4wv4INxHrxmlqcIBBFJkBzHBRLPH8bogZsU6BxVOqBgf8u4NUIqdYmFeDpG3fkfW5zHEfuR2Q4t_B_K7cVFSatC503XNVN2ODd9_0ZZk7p-0CJbnNa7ZhHdO7oALgbJyv6-XGnYEvXBt79sjrgwowMqLcR3iC3fXlsvtb5A0ieC2WHa2sYNX2eI5LjxgQ9ZLf4CVVm7WGszN793MbQz_09rxxCCQY0mW7URsmYpeHlu-pG9Ytr0oL32g8Rlum23a6Z5Yl-MZMYoMaZ55R2UD16rNh4uySBf6aT_ssxy6B7iwzjWTYSIaLfiL56QOWiBijBbNFn5MUs8QWCnbP09FkmYTEGz253ZQamUfzx-RR69fQDxakT8hEN0_JzrElRr-a0vlQ59dM6Q49HijTr56RHy2SqdIUkExbJNMxkq9_WhRTg2IQowOKr39VeOkIwVTTEYJtu9QgGPc7BFNd0R7BdEDwc3Ky_2m-d-C2S4W4RcAFc7kv0lSD6RvBoBQVqRIhl5ylQSx5moR5IJI8UpFfiCSQXGnBE7CEyyKOY1X4MghfkK0K7vuSUOlrEZZahQqcdSZSKUoVgB-ihGIiLvg2mXZvPbuwjDDZHZreJrzTTNYatdZYzQBpd1346n73eU0eDp_GG7K1ulzrt2Avr-Q7g7E_7TbEKw
link.rule.ids 315,786,790,27957,27958
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impacto+de+las+alertas+farmacoterap%C3%A9uticas+sobre+la+prescripci%C3%B3n+de+clopidogrel+e+inhibidores+de+la+bomba+de+protones+en+pacientes+ingresados&rft.jtitle=Farmacia+hospitalaria&rft.au=S%C3%A1nchez+Ruiz-Gordoa%2C+M.&rft.au=Ten%C3%ADas+Burillo%2C+J.M.&rft.au=Ruiz+Mart%C3%ADn+de+la+Torre%2C+R.&rft.au=Valenzuela+G%C3%A1mez%2C+J.C.&rft.date=2012-07-01&rft.issn=1130-6343&rft.volume=36&rft.issue=4&rft.spage=250&rft.epage=255&rft_id=info:doi/10.1016%2Fj.farma.2011.08.002&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_farma_2011_08_002
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1130-6343&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1130-6343&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1130-6343&client=summon